Two conversations, not one
High-dose, tumor-directed radiation can release antigen and, rarely, contribute to an out-of-field (abscopal) response. Rarity is the finding. Do not promise it. Send curious colleagues to /abscopal.
Low-dose radiation is studied and, in some benign indications, used to calm innate inflammation. That is a different dose, a different consent and a different follow-up clock. Send them to /immunity and /arthritis.
Phrases that stay honest
- “Radiation can change how immune cells behave. That is not the same as a proven treatment for every inflammatory disease.”
- “A response outside the treated field is real and uncommon. We do not plan care on an uncommon event.”
- “The COVID lung-radiation trials taught the field that encouraging early series can fail a proper randomised test.”
- “Meeting abstracts are not papers. If there is no article DOI, we will say so.” See ASTRO 2023.
When you should stop talking and refer
Investigational infectious indications. Combination radiation–immunotherapy outside a protocol. Any request to irradiate a young patient for a self-limited inflammatory problem because “low dose is safe.” Those are Society red lines, not clinic marketing objections.
If the next step is skills, not reading, that is partner training: /pcp/training.
Informational Society education, not medical advice.